In vitro activity of mirincamycin (U24729A) against Plasmodium falciparum isolates from Gabon.
We assessed the in vitro activity of mirincamycin, a lincosamide antibiotic, against Plasmodium falciparum clinical isolates from Gabon. Growth was determined by HRP2 enzyme-linked immunosorbent assay using an adapted protocol with a prolonged incubation time (6 days) to account for antibiotic-induced delayed death. Mirincamycin's cis and trans isomers are more active (median 50% inhibitory concentrations [IC(50)s], 3.2 nM and 2.6 nM) than the comparator drugs clindamycin (IC(50), 12 nM) and doxycycline (IC(50), 720 nM), and therefore, further clinical development is promising.
Held
Jana
J
Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
Westerman
Richard
R
Kremsner
Peter G
PG
Mordmüller
Benjamin
B
D000818:Animals; D000962:Antimalarials / Q000737:chemistry / Q000494:pharmacology*; D002981:Clindamycin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D004318:Doxycycline / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D005681:Gabon; D016778:Malaria, Falciparum / Q000469:parasitology; D010963:Plasmodium falciparum / Q000187:drug effects*; D013237:Stereoisomerism
D000962:Antimalarials; D002981:Clindamycin; C000867:mirincamycin; D004318:Doxycycline